Market Research Logo
Publisher: BioSeeker Group AB
Category: Biotechnology

Biotechnology market research reports by BioSeeker Group AB

(25 reports matching your criteria)
  • Immuno-Oncology Drug Development: Analytical Tool

    ... current progress of immune-checkpoint inhibitors and CAR-T therapies to make the immune system fight cancer. Immuno-Oncology Drug Development: Analytical Tool is the must have handbook for any business developer, BI/CI operative or clinical developer who ... Read More

  • Conjugated Antibodies in Oncology: Analytical Tool

    ... novel class of anticancer treatment agents that combines the selectivity of targeted treatment with the cytotoxic potency of chemotherapy drugs. Conjugated Antibodies in Oncology: Analytical Tool is the must have handbook for any business developer, ... Read More

  • Epigenetic Therapies in Oncology: Analytical Tool

    ... under development and entering clinical trials. Epigenetic Therapies in Oncology: Analytical Tool is the must have handbook for any business developer, BI/CI operative or clinical developer who needs to be on top of this hot ... Read More

  • Targeting the CD47-SIRPA Axis in Oncology: A Competitive Assessment of Technologies, Dual Targeting, Biomarkers, Combination Therapies & More

    ... seeking to target innate immune response. This report reveals intense global interest and a growing list of stakeholders operating in this field. Users of this report get an un-biased, fact driven analysis of the position ... Read More

  • Commercial Interests at ASCO 2017 - A 1stOncology Insights Report

    ... American Society of Clinical Oncology (ASCO) Annual Meeting 2017. Break through the mountain of close 5,000 abstracts presented at ASCO 2017 with a focused entry to reveal the identity and position of more than 470 ... Read More

  • Cancer Stem Cells: Analytical Tool

    ... business development, drug development or investment perspective. BioSeeker’s Analytical Tools have proven their worth to our clients in oncology for almost two decades in their capacities covering: Target Scouting Early & Late Stage Pipeline Analysis ... Read More

  • Antibodies in Oncology: Analytical Tool

    ... business development, drug development or investment perspective. BioSeeker’s Analytical Tools have proven their worth to our clients in oncology for almost two decades in their capacities covering: Target Scouting Early & Late Stage Pipeline Analysis ... Read More

  • RNA (miRNA, RNAi & siRNA) Therapies in Cancer: Analytical Tool

    ... empower biotech/pharma professionals from a business development, drug development or investment perspective. BioSeeker’s Analytical Tools have proven their worth to our clients in oncology for almost two decades in their capacities covering: Target Scouting Early ... Read More

  • Epigenetic Therapy in Oncology: Analytical Tool

    ... a business development, drug development or investment perspective. BioSeeker’s Analytical Tools have proven their worth to our clients in oncology for almost two decades in their capacities covering: Target Scouting Early & Late Stage Pipeline ... Read More

  • Cancer Drugs with Biomarker Development: Analytical Tool

    ... from a business development, drug development or investment perspective. BioSeeker’s Analytical Tools have proven their worth to our clients in oncology for almost two decades in their capacities covering: Target Scouting Early & Late Stage ... Read More

  • Deals & Alliances in Oncology Drug Development: Analytical Tool

    ... biotech/pharma professionals from a business development, drug development or investment perspective. BioSeeker’s Analytical Tools have proven their worth to our clients in oncology for almost two decades in their capacities covering: Target Scouting Early & ... Read More

  • Antibodies in Oncology: Drug Pathway Analyzer

    ... The rational for this plethora of treatment strategies is based on our increasing understanding of the 345 drug targets that are included in this drug-pathway analyzing tool. No less than 322 of these have been ... Read More

  • RNAs (miRNA, RNAi & siRNA) in Oncology: Drug Pathway Analyzer

    ... treatment of more than 41 different tumor types. The rational for this plethora of treatment strategies is based on our increasing understanding of the 90 drug targets that are included in this drug-pathway analyzing tool. ... Read More

  • Proteins in Oncology: Drug Pathway Analyzer

    ... The rational for this plethora of treatment strategies is based on our increasing understanding of the 200 drug targets that are included in this drug-pathway analyzing tool. No less than 181 of these have been ... Read More

  • Biologicals in Oncology: Drug Pathway Analyzer

    ... The rational for this plethora of treatment strategies is based on our increasing understanding of the 674 drug targets that are included in this drug-pathway analyzing tool. No less than 607 of these have been ... Read More

  • Gene Therapy in Oncology Drug Pipeline Update

    ... accumulated number of ceased drugs over the last years amount to another 105 drugs. Gene Therapy In Oncology Drug Pipeline Update lists all drugs and gives you a progress analysis on each one of them. ... Read More

  • Biologicals in Oncology Drug Pipeline Update

    ... 2823 biological drugs in 6088 developmental projects in cancer. In addition, there are 25 suspended drugs and the accumulated number of ceased drugs over the last years amount to another 1050 drugs. Biologicals In Oncology ... Read More

  • MicroRNAs in Cancer Drug Pipeline Update

    ... minimal toxicities either as a monotherapy or perhaps even more likely in a combinatorial drug setting. miRNA may also hold great potential as biomarkers, albeit a lot of work is a head of us and ... Read More

  • Cancer Stem Cells Drug Pipeline Update

    ... and cancer drugs which are inhibitors of the Hedgehog, Notch, and WNT Pathway. These developmental pathways are frequently activated in neoplasms, and particularly in the rare subpopulation of cancer stem cells. There are today 441 ... Read More

  • The Latest Sales Figures in Oncology Drug Pipeline Update

    ... companies to progressive biotech companies. The analysis leverages the power of BioSeeker's 1stOncology intelligence which combines company disclosed product sales and detailed drug development information. The results is not only a unique insight into the ... Read More

  • Fierce 15 in Oncology Drug Pipeline Update

    ... award are aiming at breakthroughs and big things, not at being 'me-too'. This unique product, the 'Fierce 15 in Oncology Drug Pipeline Update' gathers the last six years (2010-2015) of Fierce 15 awards and identifies ... Read More

  • Antibodies in Oncology Drug Pipeline Update

    ... the second wave in the lucrative field of therapeutic antibodies. There are today 542 companies plus partners developing 1308 antibody drugs in 3051 developmental projects in cancer. In addition, there are 4 suspended drugs and ... Read More

  • RNA (miRNA, RNAi & siRNA) Therapy in Oncology Drug Pipeline Update

    ... or protein-based therapies. There are today 103 companies plus partners developing 131 RNA (miRNA, RNAi & siRNA) drugs in 198 developmental projects in cancer. In addition, there are 2 suspended drugs and the accumulated number ... Read More

  • Proteins in Oncology Drug Pipeline Update

    ... developmental projects in cancer. In addition, there are 2 suspended drugs and the accumulated number of ceased drugs over the last years amount to another 207 drugs. Proteins In Oncology Drug Pipeline Update lists all ... Read More

  • CAR-T Therapies in Oncology Drug Pipeline Update 2015

    ... drug. In this regard, we have already witnessed the stellar results by Novartis and Penn University on CTL019 that left 92% of patients cancer-free in a leukemia study and performed well against lymphomas in clinical ... Read More

Research Assistance

Biotechnology market research reports by BioSeeker Group AB

Join Alert Me Now!

Sign Up

Find out more on our blog